Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246325 | 0.90 | SCN9A (0.46) | SCN9ASCN5ANTRK1TSHRHTT | |
| SCHEMBL4036879 | 0.87 | NPSR1 (0.56) | SCN9ASCN5ANTRK1TSHRHTT | |
| SCHEMBL1247566 | 0.83 | SCN9A (0.59) | SCN9ASCN5ANTRK1NPSR1MAPT | |
| SCHEMBL1247206 | 0.82 | SCN9A (0.61) | SCN9ASCN5ANTRK1HTTNPSR1 | |
| SCHEMBL4036846 | 0.82 | GAA (0.52) | SCN9ASCN5ANTRK1TSHRHTT | |
| SCHEMBL4038287 | 0.82 | NPSR1 (0.55) | SCN9ASCN5ANTRK1TSHRHTT | |
| SCHEMBL1245064 | 0.81 | SCN9A (0.48) | SCN9ASCN5ANTRK1NPSR1MAPT | |
| SCHEMBL1245362 | 0.81 | SCN9A (0.57) | SCN9ASCN5ANTRK1NPSR1MAPT | |
| SCHEMBL1245322 | 0.81 | SCN9A (0.57) | SCN9ASCN5ANTRK1NPSR1MAPT | |
| SCHEMBL1245296 | 0.81 | SCN9A (0.55) | SCN9ASCN5ANTRK1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964975-B2 | Isoxazole and thiazole compounds and use thereof as medicine | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-11-15 | — | — | US | claimed |
| EP-1258484-B1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6964975-B2 | Isoxazole and thiazole compounds and use thereof as medicine | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-11-15 | — | — | US | disclosed |
| US-20030114505-A1 | Novel isoxazole and thiazole compounds and use thereof as drugs | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1258484-A1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114505-A1 | Novel isoxazole and thiazole compounds and use thereof as drugs | LPAR3, LPAR1, LPAR4 | SCN9A 3060/4885SCN5A 3149/4885NTRK1 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.